RecruitingNot ApplicableNCT06424106

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Conditions

Prediabetes

Summary

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Eligibility

Min Age: 25 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating what happens to blood sugar and insulin levels when glucagon — a hormone that normally raises blood sugar — is given to people without Type 2 diabetes who are fasting. It aims to better understand normal and early-stage abnormal blood sugar regulation. **You may be eligible if...** - You have normal or borderline-elevated fasting blood sugar (prediabetes range) - You have normal or mildly impaired glucose tolerance **You may NOT be eligible if...** - Your HbA1c is 6.5% or higher (indicating diabetes) - You take any blood sugar medication such as metformin - You are pregnant - You have had upper abdominal surgery (such as gastric banding) - You have an active illness, cancer, or significant blood vessel complications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.